10 completed, 1 terminated, 1 withdrawn. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 10, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Bacterial Infection: new trials by email Literature Review of Bacterial Infection trials Research Report on Bacterial Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Intravenous Apramycin in Adults Apramycin (EBL-1003) - Bacterial Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2023-06-16 | 2025-03-06 |
| Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) Ertapenem, Placebo, WCK 6777 - Bacterial Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 54 | 2023-04-19 | 2025-01-20 |
| A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam AZACTAM, Ceftazidime-Avibactam - Bacterial Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2019-07-09 | 2022-06-07 |
| Intravenous Fosfomycin Pharmacokinetics Study Fosfomycin disodium - Bacterial Infection, Multiple-drug Resistance | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 39 | 2019-06-27 | 2023-10-23 |
| Pharmacokinetics and Safety of Solithromycin in Adolescents and Children solithromycin - Bacterial Infection | Phase 1 | Completed | Melinta Therapeutics, Inc. | 84 | 2015-01-01 | 2017-06-09 |
| Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg TR-701 FA - Bacterial Infection | Phase 1 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 20 | 2010-12-08 | 2019-11-15 |
| Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients TR-701 FA - Bacterial Infection | Phase 1 | Completed | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 20 | 2010-06-02 | 2018-12-07 |
| Cerebral Antibiotics Distribution After Acute Brain Injury cefotaxime, Metronidazole, Ciprofloxacin - Bacterial Infection, Brain Injury | Phase 1 | Completed | Poitiers University Hospital | 18 | 2009-09-01 | 2016-10-11 |
| Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients human lactoferrin (hLF1-11) - Fungal Infection, Bacterial Infection | Phase 1 / Phase 2 | Withdrawn | AM-Pharma | 2008-11-01 | 2015-06-30 | |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416 GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg) - Bacterial Infection, Infections, Bacterial | Phase 1 | Terminated | GlaxoSmithKline | 96 | 2007-06-01 | 2017-01-20 |
| Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal skin cleansing with chlorhexidine (0.25%, 0.5%, 1%) - Bacterial Infection | Phase 1 / Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 286 | 2006-01-01 | 2010-04-05 |
| An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates Azithromycin - Ureaplasma, Bacterial Infection | Phase 1 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 16 | 2005-09-01 | 2008-09-26 |
Bacterial Infections (12) · Brain Injuries (1) · Infections (1) · Mycoses (1) · Neutropenia (1)
Bacterial Infections and Mycoses (12) · Infections (11) · Agranulocytosis (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Craniocerebral Trauma (1) · Cytopenia (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukocyte Disorders (1) · Leukopenia (1) · Nervous System Diseases (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Azithromycin (1) · Aztreonam (1) · Cefotaxime (1) · Chlorhexidine (1) · Ciprofloxacin (1) · Ertapenem (1) · Ketoconazole (1) · Metronidazole (1) · apramycin (1) · avibactam, ceftazidime drug combination (1) · solithromycin (1) · zidebactam (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) · Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · AM-Pharma (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GlaxoSmithKline (1) · Johns Hopkins Bloomberg School of Public Health (1) · Melinta Therapeutics, Inc. (1) · Poitiers University Hospital (1)
United States (7) · Australia (1) · Bulgaria (1) · France (1) · Nepal (1) · Netherlands (1)
David Edwards, Pharm.D. (1) · David Nicolau, PharmD (1) · Elias Tessema, M.D. (1) · Jacob Aranda, M.D., Ph.D. (1) · Luke C Mullany, PhD (1) · Michael Cohen-Wolkowiez, MD (1) · Peter J Donnelly, PhD (1)
PMID 22330925, PMID 29891609, PMID 31318840, PMID 39772650, PMID 42809435
5UM1AI104681-09 (1), R01HD044004 (1)